RAPT Therapeutics Inc (FRA:0RA)
€ 2.66 0 (0%) Market Cap: 56.69 Mil Enterprise Value: -32.34 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 41/100

Rapt Therapeutics Inc at Wells Fargo Healthcare Conference Transcript

Sep 08, 2022 / 05:55PM GMT
Release Date Price: €13.2
Unidentified Participant

Great. Thanks, everyone, for joining us. Let's get started. We are very fortunate to have RAPT CEO, Brian Wong with us today for a fireside chat. Hi, Brian. Thank you for being here.

Brian Wong
RAPT Therapeutics, Inc. - President & CEO

Thank you, [Ian]. Appreciate the opportunity.

Questions & Answers

Unidentified Participant

Yes. So could you -- I think, for people who may not be familiar with -- to the RAPT story, could you give a brief overview about the company's platform and programs?

Brian Wong
RAPT Therapeutics, Inc. - President & CEO

Sure, absolutely. So RAPT Therapeutics is focused on the discovery, development, and commercialization of oral small molecule that targets the immunological drivers of, both inflammation and cancer.

We have two lead programs. Our lead program in inflammation is called RPT193. This is currently in a Phase 2b trial in patients with moderate to severe atopic dermatitis. And we've demonstrated in our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot